Evidence map›Paper›PMID 36611344›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Prognostic Utility of CD47 in Cancer of the Uterine Cervix and the Sensitivity of Immunohistochemical Scores.

Angel Yordanov, Velizar Shivarov, Stoyan Kostov, Yonka Ivanova, Polina Dimitrova, Savelina Popovska, Eva Tsoneva, Mariela Vasileva-Slaveva

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Angel YordanovDepartment of Gynaecological Oncology, Medical University Pleven, 5800 Pleven, Bulgaria.ORCID 0000-0002-7719-382X
Velizar ShivarovResearch Institute, Medical University Pleven, 5800 Pleven, Bulgaria.ORCID 0000-0001-5362-7999
Stoyan KostovDepartment of Gynecology, St. Anna University Hospital, Medical University-Varna "Prof. Dr. Paraskev Stoyanov", 9000 Varna, Bulgaria.ORCID 0000-0002-5279-3095
Yonka IvanovaDepartment of Gynecology, St. Anna University Hospital, Medical University-Varna "Prof. Dr. Paraskev Stoyanov", 9000 Varna, Bulgaria.
Polina DimitrovaDepartment of Pathology, Medical University-Pleven, 5800 Pleven, Bulgaria.
Savelina PopovskaDepartment of Pathology, Medical University-Pleven, 5800 Pleven, Bulgaria.
Eva TsonevaDepartment of Obstetrics and Gynecology, Shterev Hospital, 1000 Sofia, Bulgaria.
Mariela Vasileva-SlavevaResearch Institute, Medical University Pleven, 5800 Pleven, Bulgaria.ORCID 0000-0002-6180-3742
Medical University Pleven · BGDr. Shterev Hospital · BGMedical University of Varna · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer of the uterine cervix (CUC) is still one of the most frequent oncological diagnoses in women. The specific interactions between the tumor cells of CUC and the cells and tissues in the tumor microenvironment can affect cancer cells' invasive and metastatic potential and can modulate tumor's progression and death. CD47 is a trans-membranous immunoglobulin, expressed in many cells. It protects the cells from being destroyed by the circulating macrophages.

aimWe aimed to evaluate the prognostic role of CD47 expressed in the tumor tissues of patients with CUC for tumor progression and to find the most sensitive immunohistochemical score for defining the cut-off significantly associated with tumor biology and progression. MATERIALS AND

methodsParaffin-embedded tumor tissues from 86 patients with CUC were included in the study. Clinico-morphological data for patients, such as age and stage at diagnosis according to FIGO and TNM classification, were obtained from the hospital electronic medical records. Immunohistochemical staining was performed with rabbit recombinant monoclonal CD47 antibody (Clone SP279). The final result was interpreted based on three reporting models in immunohistochemistry: H-score, Allred score and combined score.

resultsThe expression of CD47 was higher in tumors limited in the cervix compared with those invading other structures, and it did not depend on the nodal status. The results of immunohistochemical staining were similar regardless of which immunohistochemical method was used. The most significant correlation with TNM stage was observed with the H-score (

conclusionThe expression of CD47 in the cancer cells is prognostic for tumor invasion in the surrounding structures, independent of lymph node engagement. The H-score is the most sensitive immunohistochemical score to describe tumor stage. To the best of our knowledge, this is the first study evaluating the significance of CD47 expression in CUC.

Indexed as

cancer of the uterine cervixCD47expressionimmunohistochemical scores

Identifiers

PMID36611344
PMCPMC9818840
OpenAlexW4313247154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.